Last reviewed 2026-05-31 · How we verify

0.5mg Varenicline b.i.d. (0-5mg-varenicline-b-i-d)

Pfizer Inc. · preclinical active ✓ Verified May 2026

0.5mg Varenicline b.i.d. (generic name: 0-5mg-varenicline-b-i-d) is a Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drug developed by Pfizer Inc.. It is currently in preclinical development.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t

0.5mg Varenicline taken twice a day is used to treat tobacco dependence, withdrawal symptoms, and smoking cessation. Varenicline's mechanism of action involves binding to nicotinic acetylcholine receptors, which is consistent with its use in smoking cessation.

Likelihood of approval

8% vs 5% industry baseline

If approved by FDA: likely 2036–2040

Steps remaining: Phase 1 → Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Low

Why this estimate

Baseline preclinical → approval rate +5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2036–2040	—
EMA	EU	2037–2041	+0.7 yr
MHRA	GB	2037–2041	+0.7 yr
Health Canada	CA	2037–2042	+0.9 yr
TGA	AU	2037–2042	+1.2 yr
PMDA	JP	2037–2042	+1.5 yr
NMPA	CN	2038–2043	+2.3 yr
MFDS	KR	2037–2042	+1.4 yr
CDSCO	IN	2037–2043	+1.8 yr
ANVISA	BR	2038–2043	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	0-5mg-varenicline-b-i-d
Sponsor	Pfizer Inc.
Drug class	Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t
Therapeutic area	Other
Phase	preclinical

Mechanism of action

Varenicline works by attaching to nicotine receptors in your brain—the same receptors that nicotine normally stimulates. However, varenicline only partially activates these receptors, providing just enough stimulation to significantly reduce the intense cravings and withdrawal discomfort that smokers experience when quitting. This partial activation keeps your brain's reward system somewhat satisfied without the full "high" that smoking provides. The second part of varenicline's strategy is equally important: because it occupies these same nicotine receptors, it physically blocks actual nicotine from attaching to them. If you slip and smoke a cigarette while taking varenicline, the nicotine cannot reach its target receptors as effectively, which means smoking no longer produces the satisfying and reinforcing sensation you're accustomed to. This removes much of the motivation to keep smoking. The 0.5mg twice-daily dosing provides continuous brain coverage throughout the day, maintaining steady levels of the medication so you get consistent relief from cravings. This regular dosing schedule, combined with varenicline's two-pronged approach, makes it one of the most effective pharmaceutical aids for smoking cessation.

Approved indications

No approved indications tracked.

Pipeline indications

Tobacco Dependence — preclinical

Common side effects

No common side effects on file.

Key clinical trials

Varenicline OTC Trial on Efficacy and Safety (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

0.5mg Varenicline b.i.d. CI brief — competitive landscape report
0.5mg Varenicline b.i.d. updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about 0.5mg Varenicline b.i.d.

What is 0.5mg Varenicline b.i.d.?

0.5mg Varenicline b.i.d. (0-5mg-varenicline-b-i-d) is a Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drug developed by Pfizer Inc..

How does 0.5mg Varenicline b.i.d. work?

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t

Who makes 0.5mg Varenicline b.i.d.?

0.5mg Varenicline b.i.d. is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of 0.5mg Varenicline b.i.d.?

0-5mg-varenicline-b-i-d is the generic (nonproprietary) name of 0.5mg Varenicline b.i.d..

What drug class is 0.5mg Varenicline b.i.d. in?

0.5mg Varenicline b.i.d. belongs to the Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t class. See all Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drugs at /class/varenicline-is-classified-as-a-selective-nicotine-receptor-partial-agonist-snrpa-that-works-both-t.

What development phase is 0.5mg Varenicline b.i.d. in?

0.5mg Varenicline b.i.d. is in preclinical.

Drug class: All Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both t drugs
Manufacturer: Pfizer Inc. — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing